CNV2197944
/ Biogen
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 29, 2013
A phase 1 ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidate
(PipelineReview)
- "Convergence expects to report data from the TN trial with CNV1014802 and the postherpetic neuralgia Phase II study with CNV2197944, in the first half of 2014."
Anticipated P2 data • Pain
November 21, 2011
Convergence Pharmaceuticals initiates phase I multiple ascending dose study for CNV2197944
(PRNewswire)
- P1, N=NA; Convergence announces initiation of multiple ascending dose P1 study of CNV2197944, for the treatment of chronic pain; The study is expected to conclude in Q2 2012; The first human single ascending dose P1 study data demonstrated ideal pharmacokinetic profile and excellent safety and tolerability; CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis
Anticipated P1 data • P1 preliminary data • P1 trial initiation • Pain
October 30, 2014
Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia
(clinicaltrials.gov)
- P2; N=103; Completed; Sponsor: Convergence Pharmaceuticals; Active, not recruiting -> Completed
Trial completion • Biosimilar • Pain
1 to 3
Of
3
Go to page
1